In October and November 2023, CMS held one listening session for each of the 10 negotiated drugs . These sessions, though not required by statute, were the Agency's response to the patient community's request that CMS create a mechanism to hear from people with lived experience with the selected drugs and the conditions they treat. Many of the Roundtable attendees participated in listening sessions or prepared patient advocate speakers. Others did neither but had a strong interest in the sessions and/or are subject matter experts on patient engagement. Many of the participants submitted data through the Agency's Information Collection Request (ICR) either in addition to participating in the listening sessions or in lieu of participating. For a full list of attendees at the Roundtable, see Appendix A.